Cerus (CERS) to Post Quarterly Earnings on Thursday

Cerus (NASDAQ:CERS) is expected to be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Cerus to announce earnings of ($0.0133) per share and revenue of $62.90 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $59.89 million during the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. On average, analysts expect Cerus to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Performance

Shares of CERS stock opened at $3.07 on Tuesday. Cerus has a 52 week low of $1.15 and a 52 week high of $3.47. The company has a market capitalization of $615.14 million, a price-to-earnings ratio of -61.40 and a beta of 1.77. The company has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $2.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63.

Insiders Place Their Bets

In related news, insider Chrystal Jensen sold 24,329 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total transaction of $71,527.26. Following the sale, the insider owned 966,657 shares of the company’s stock, valued at $2,841,971.58. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Dennis Green sold 33,676 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total value of $99,007.44. Following the sale, the chief financial officer directly owned 1,062,188 shares in the company, valued at $3,122,832.72. This represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 256,071 shares of company stock valued at $747,894 in the last quarter. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Cerus

Several hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC raised its position in shares of Cerus by 152.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 62,854 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Millennium Management LLC increased its stake in Cerus by 12.0% in the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after acquiring an additional 344,395 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Cerus in the first quarter valued at approximately $32,000. Finally, Rhumbline Advisers raised its position in Cerus by 6.8% during the second quarter. Rhumbline Advisers now owns 268,946 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 17,039 shares in the last quarter. 78.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CERS has been the subject of several research reports. Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Friday, May 1st. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a report on Thursday, June 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.00.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.